Metabolisches Syndrom und gastrointestinale Krebsvorsorge

Zusammenfassung

Krebs und Herzkreislauferkrankungen sind die beiden führenden Todesursachen beim metabolischen Syndrom. Je mehr Komponenten des metabolischen Syndroms (MetS) vorliegen, umso stärker steigt das gastrointestinale (GI) Krebsrisiko. Das MetS ist ursächlich mit Adenokarzinomen der Speiseröhre, des Magens, des Pankreas, der Gallenwege, der Leber und des Dickdarms assoziiert. Das MetS erhöht die GI-Krebssterblichkeit bis zum 2,4-fachen. Bei adipösen MetS-Patienten kann die dauerhafte Gewichtsreduktion das GI-Krebsrisiko senken. Dem MetS vorzubeugen, es effektiv zu behandeln sowie regelmäßig an der GI-Krebsvorsorge teilzunehmen ist wichtig und verringert das Risiko, an GI-Karzinomen zu erkranken und daran zu versterben.

Abstract

Cancer has become a leading cause of death among patients with metabolic syndrome (MetS). The more components of MetS a patient has, the higher his cancer risk is. MetS is causally associated with colorectal, pancreatic, gallbladder, biliary, hepatocellular, gastric and esophageal adenocarcinomas. MetS increases cancer mortality up to 2.4-fold. Intentional long-term weight loss reduces the excess cancer risk of obese MetS-patients. Preventing and treating the MetS together with GI cancer screening is effective and decreases the burden of GI cancer mortality significantly.

Schlüsselwörter

Tumor - Neoplasie - Leber - Darm - Pankreas

Keywords

tumor - neoplasm - hepatocellular - colon - pancreas

Publication History

Received: 02 July 2022

Accepted: 06 October 2022

Article published online:
15 November 2022

• Literatur

• 1 Wengler A, Rommel A, Plaß D. et al. Years of life lost to death—a comprehensive analysis of mortality in Germany conducted as part of the BURDEN 2020 project. Dtsch Arztebl Int 2021; 118: 137-144 DOI: 10.3238/arztebl.m2021.0148.
• 2 Dagenais GR, Leong DP, Rangarajan S. et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785-794
• 3 Wu Y, Li Y, Giovannucci E. Potenzial Impact of Time Trend of Lifestyle Risk Factors on Burden of Major Gastrointestinal Cancers in China. Gastroenterology 2021; 161 (06) 1830-1841.e8 DOI: 10.1053/j.gastro.2021.08.006.
• 4 Liu Y, Yan C, Yin S. et al. Genetic risk, metabolic syndrome, and gastrointestinal cancer risk: A prospective cohort study. Cancer Med 2022; DOI: 10.1002/cam4.4923.
• 5 López-Jiménez T, Duarte-Salles T, Plana-Ripoll O. et al. Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study. PLoS One 2022; 17 (03) e0264634 DOI: 10.1371/journal.pone.0264634.
• 6 Rothwell JA, Jenab M, Karimi M. et al. Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data. Clin Gastroenterol Hepatol 2021; DOI: 10.1016/j.cgh.2021.10.016.
• 7 Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord 2009; 7 (04) 279-288 DOI: 10.1089/met.2008.0065.
• 8 Esposito K, Chiodini P, Colao A. et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012; 35 (11) 2402-2411 DOI: 10.2337/dc12-0336.
• 9 Lee JS, Cho SI, Park HS. Metabolic syndrome and cancer-related mortality among Korean men and women. Ann Oncol 2010; 21 (03) 640-645 DOI: 10.1093/annonc/mdp344.
• 10 Gathirua-Mwangi WG, Monahan PO, Murage MJ. et al. Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control 2017; 28 (02) 127-136 DOI: 10.1007/s10552-016-0843-1.
• 11 Watanabe J, Kakehi E, Kotani K. et al. Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: the Jichi Medical School Cohort Study. Diabetol Metab Syndr 2019; 11 DOI: 10.1186/s13098-018-0398-2.
• 12 Tran TT, Gunathilake M, Lee J. et al. Association between metabolic syndrome and its components and incident colorectal cancer in a prospective cohort study. Cancer 2022; 128 (06) 1230-1241 DOI: 10.1002/cncr.34027.
• 13 Ulmer H, Borena W, Rapp K. et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 2009; 101 (07) 1202-1206 DOI: 10.1038/sj.bjc.6605264.
• 14 Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010; 55 (25) 2846-2854 DOI: 10.1016/j.jacc.2009.12.069.
• 15 Stocks T, Van Hemelrijck M, Manjer J. et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 2012; 59 (04) 802-810 DOI: 10.1161/HYPERTENSIONAHA.111.189258.
• 16 Chen H, Zheng X, Zong X. et al. Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut 2021; 70 (06) 1147-1154 DOI: 10.1136/gutjnl-2020-321661.
• 17 Jin EH, Han K, Lee DH. et al. Association between Metabolic Syndrome and the Risk of Colorectal Cancer Diagnosed before 50 years According to Tumor Location. Gastroenterology 2022; DOI: 10.1053/j.gastro.2022.05.032.
• 18 Lu L, Koo S, McPherson S. et al. Systematic review and metaanalysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Dis 2022; DOI: 10.1111/codi.16092.
• 19 Awwad F, Ozga AK, Amin T. et al. Metabolic syndrome is associated with impaired survival after surgery for pancreatic neuroendocrine tumors. Neuroendocrinology 2022; DOI: 10.1159/000524366.
• 20 Aminian A, Wilson R, Al-Kurd A. et al. Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity. JAMA 2022; DOI: 10.1001/jama.2022.9009.
• 21 Célind J, Bygdell M, Martikainen J. et al. Childhood overweight and risk of obesity-related adult cancer in men. Cancer Commun (Lond) 2022; DOI: 10.1002/cac2.12286.
• 22 Sung H, Siegel RL, Rosenberg PS. et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4: e137-147
• 23 Schell D, Ullah S, Brooke-Smith ME. et al. Gastrointestinal Adenocarcinoma Incidence and Survival Trends in South Australia, 1990–2017. Cancers (Basel) 2022; 14 (02) 275 DOI: 10.3390/cancers14020275.
• 24 Park JH, Han K, Hong JY. et al. Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. Gastroenterology 2022; 162 (02) 509-520.e7 DOI: 10.1053/j.gastro.2021.09.070.
• 25 Park JH, Hong JY, Park YS. et al. Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population-based cohort study. Eur J Cancer 2021; 155: 97-105 DOI: 10.1016/j.ejca.2021.06.052.
• 26 Moore SC, Lee IM, Weiderpass E. et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med 2016; 176: 816-825
• 27 Papadimitriou N, Markozannes G, Kanellopoulou A. et al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. Nat Commun 2021; 12: 4579 DOI: 10.1038/s41467-021-24861-8.
• 28 Rustgi VK, Li Y, Gupta K. et al. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021; DOI: 10.1053/j.gastro.2021.03.021.
• 29 Sjöholm K, Carlsson LMS, Svensson PA. et al. Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-Term Results From the Swedish Obese Subjects Study. Diabetes Care 2021; dc211335 DOI: 10.2337/dc21-1335.
• 30 Syn NL, Cummings DE, Wang LZ. et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet 2021; 397: 1830-1841 DOI: 10.1016/S0140-6736(21)00591-2.
• 31 Vuik F, Nieuwenburg S, Bardou M. et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826
• 32 Li H, Boakye D, Chen X. et al. Associations of Body Mass Index at Different Ages With Early-Onset Colorectal Cancer. Gastroenterology 2022; 162 (04) 1088-1097.e3 DOI: 10.1053/j.gastro.2021.12.239.
• 33 Esposito K, Chiodini P, Capuano A. et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013; 44 (03) 634-647 DOI: 10.1007/s12020-013-9939-5.
• 34 Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control 2015; 26 (02) 257-268 DOI: 10.1007/s10552-014-0507-y.
• 35 El Herrag SE, Traoré Y, Khaled MB. Metabolic Syndrome and Risk of Colorectal Adenoma and Colorectal Cancer: A Meta-Analysis. The North African Journal of Food and Nutrition Research 2017; 1 (02) 30-45 DOI: 10.51745/najfnr.1.2.30-45.
• 36 Li X, Chen H, Wang G. et al. Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. Front Oncol 2019; 9: 1047 DOI: 10.3389/fonc.2019.01047.
• 37 Shen X, Wang Y, Zhao R. et al. Metabolic syndrome and the risk of colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2021; 36 (10) 2215-2225 DOI: 10.1007/s00384-021-03974-y.
• 38 Milano A, Bianco MA, Buri L. et al. Metabolic syndrome is a risk factor for colorectal adenoma and cancer: a study in a White population using the harmonized criteria. Therap Adv Gastroenterol 2019; 12: 1756284819867839 DOI: 10.1177/1756284819867839.
• 39 Santiago CN, Rifkin S, Drewes J. et al. Self-reported Metabolic Risk Factor Associations with Adenomatous, Sessile Serrated, and Synchronous Adenomatous and Sessile Serrated Polyps. Cancer Prev Res (Phila) 2021; 14 (07) 697-708 DOI: 10.1158/1940-6207.CAPR-20-0664.
• 40 Cheng WC, Chen PJ, Kang JW. et al. Age, male sex, smoking and metabolic syndrome as risk factors of advanced colorectal neoplasia for fecal immunochemical test negative patients. J Formos Med Assoc 2022; 121: 402-408 DOI: 10.1016/j.jfma.2021.05.025.
• 41 Hu NC, Chen JD, Lin YM. et al. Stepwise relationship between components of metabolic syndrome and risk of colorectal adenoma in a Taiwanese population receiving screening colonoscopy. J Formos Med Assoc 2011; 110 (02) 100-108 DOI: 10.1016/S0929-6646(11)60016-8.
• 42 Yeh JH, Lin CW, Wang WL. et al. Positive Fecal Immunochemical Test Strongly Predicts Adenomas in Younger Adults With Fatty Liver and Metabolic Syndrome. Clin Transl Gastroenterol 2021; 12 (02) e00305 DOI: 10.14309/ctg.0000000000000305.
• 43 Elangovan A, Skeans J, Landsman M. et al. Colorectal Cancer, Age, and Obesity-Related Comorbidities: A Large Database Study. Dig Dis Sci 2021; 66 (09) 3156-3163 DOI: 10.1007/s10620-020-06602-x.
• 44 Davidson KW, Barry MJ. US Preventive Services Task Force. et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325 (19) 1965-1977 DOI: 10.1001/jama.2021.6238.
• 45 Chen Y, Li X, Wu S. et al. Metabolic syndrome and the incidence of hepatocellular carcinoma: a meta-analysis of cohort studies. Onco Targets Ther 2018; 11: 6277-6285 DOI: 10.2147/OTT.S154848.
• 46 Häggström C, Jonsson H, Bjørge T. et al. Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals. Int J Cancer 2020; 146 (01) 58-67 DOI: 10.1002/ijc.32240.
• 47 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021; 73 (Suppl. 01) 4-13 DOI: 10.1002/hep.31288.
• 48 Simon TG, King LY, Chong DQ. et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 2018; 67 (05) 1797-1806 DOI: 10.1002/hep.29660.
• 49 Chen CL, Yang HI, Yang WS. et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135 (01) 111-121 DOI: 10.1053/j.gastro.2008.03.073.
• 50 Zou B, Odden MC, Nguyen MH. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2022; DOI: 10.1016/j.cgh.2022.01.057.
• 51 Pinyopornpanish K, Al-Yaman W, Butler RS. et al. Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis. Am J Gastroenterol 2021; 116: 2258-2269
• 52 Wang Y, Wang W, Wang M. et al. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2022; 2022: 5389044 DOI: 10.1155/2022/5389044.
• 53 Chiu WC, Shan JC, Yang YH. et al. Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder. Drug Alcohol Depend 2021; 228: 109096 DOI: 10.1016/j.drugalcdep.2021.109096.
• 54 Lee HL, Lee SW, Jang JW. et al. Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2022; 28 (03) 397-406 DOI: 10.1002/lt.26258.
• 55 Khajeh E, Moghadam AD, Eslami P. et al. Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery. BMC Cancer 2022; 22 (01) 91 DOI: 10.1186/s12885-022-09192-1.
• 56 Shawcross DL, Suddle A. Statins: A Panacea to Reduce Mortality in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma?. Liver Transpl 2022; 28 (03) 357-358 DOI: 10.1002/lt.26381.
• 57 Hajifathalian K, Tafesh Z, Rosenblatt R. et al. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. J Clin Gastroenterol 2022; 56 (02) 173-180 DOI: 10.1097/MCG.0000000000001503.
• 58 Xiong J, Lu X, Xu W. et al. Metabolic syndrome and the risk of cholangiocarcinoma: a hospital-based case–control study in China. Cancer Manag Res 2018; 10: 3849-3855 DOI: 10.2147/CMAR.S175628.
• 59 Cheung KS, Yeung YWM, Wong WS. et al. Statins associate with lower risk of biliary tract cancers: A systematic review and meta-analysis. Cancer Med 2022; DOI: 10.1002/cam4.4942.
• 60 Wang J, Zhuge J, Feng D. et al. Mendelian randomization study of circulating lipids and biliary tract cancer among East Asians. BMC Cancer 2022; 22: 273 DOI: 10.1186/s12885-022-09382.
• 61 Santos AP, Santos AC, Castro C. et al. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2018; 10 (09) 293 DOI: 10.3390/cancers10090293.
• 62 Barrea L, Muscogiuri G, Modica R. et al. Cardio-Metabolic Indizes and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021; 12: 649496 DOI: 10.3389/fendo.2021.649496.
• 63 Nagel G, Bjørge T, Jaensch A. et al. Metabolic factors and the risk of small intestine cancers: Pooled study of 800 000 individuals in the metabolic syndrome and cancer project. Int J Cancer 2021; 149 (01) 66-74 DOI: 10.1002/ijc.33530.
• 64 Natalicchio A, Faggiano A, Zatelli MC. et al. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2022; 169: 103572 DOI: 10.1016/j.critrevonc.2021.103572.
• 65 Awwad F, Ozga AK, Amin T. et al. Metabolic syndrome is associated with impaired survival after surgery for pancreatic neuroendocrine tumors. 2022; DOI: 10.1159/000524366.
• 66 Zhang J, Wu H, Wang R. Metabolic syndrome and esophageal cancer risk: a systematic review and metaanalysis. Diabetol Metab Syndr 2021; 13 (01) 8 DOI: 10.1186/s13098-021-00627-6.
• 67 Lee JE, Han K, Yoo J. et al. Association of Metabolic Parameter Variability with Esophageal Cancer Risk: A Nationwide Population-Based Study. J Pers Med 2022; 12 (03) 375 DOI: 10.3390/jpm12030375.
• 68 Elliott JA, Reynolds JV. Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma. Front Oncol 2021; 11: 627270 DOI: 10.3389/fonc.2021.627270.
• 69 Mariani M, Sassano M, Boccia S. Metabolic syndrome and gastric cancer risk: a systematic review and meta-analysis. Eur J Cancer Prev 2021; 30 (03) 239-250 DOI: 10.1097/CEJ.0000000000000618.
• 70 https://www.gastroenterologyadvisor.com/meetings/ddw-2022/esophageal-cancer-and-barrett-esophagus-increasing-in-middle-aged-adults/
• 71 Bergquist JR, Leiting JL, Habermann EB. et al. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery 2019; 166 (04) 547-555
• 72 Jun JK, Choi KS, Lee HY. et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328
• 73 Yu Z, Zuo T, Yu H. et al. Outcomes of upper gastrointestinal cancer screening in high-risk individuals: a population-based prospective study in Northeast China. BMJ Open 2022; 12 (02) e046134 DOI: 10.1136/bmjopen-2020-046134.
• 74 Xia JY, Aadam AA. Advances in screening and detection of gastric cancer. J Surg Onco 2022; 125 (07) 1104-1109 DOI: 10.1002/jso.26844.
• 75 Bouras E, Tsilidis KK, Triggi M. et al. Diet and Risk of Gastric Cancer: An Umbrella Review. Nutrients 2022; 14 (09) 1764 DOI: 10.3390/nu14091764.
• 76 Knudsen MD, Wang L, Wang K. et al. Changes in Lifestyle Factors After Endoscopic Screening: A Prospective Study in the United States. Clin Gastroenterol Hepatol 2022; 20 (06) e1240-e1249 DOI: 10.1016/j.cgh.2021.07.014.
• 77 Zhou CB, Pan SY, Jin P. et al. Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer. Gastroenterology 2022; DOI: 10.1053/j.gastro.2022.02.015.
• 78 Seo SI, Park CH, Kim TJ. et al. Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer Med 2022; 11 (04) 1217-1231 DOI: 10.1002/cam4.4514.
• 79 Scherübl H. Tobacco Smoking and Gastrointestinal Cancer Risk. Visc Med 2022; 38: 217-222 DOI: 10.1159/000523668.